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Abstract
Telomerase expression represents a good target for
cancer gene therapy. The promoters of the core telo-
merase catalytic [human telomerase reverse transcrip-
tase (hTERT)] and RNA [human telomerase RNA (hTR)]
subunits show selective activity in cancer cells but not
in normal cells. This property can be harnessed to ex-
press therapeutic transgenes in a wide range of cancer
cells. Unfortunately, weak hTR and hTERT promoter
activities in some cancer cells could limit the target cell
range. Therefore, strategies to enhance telomerase-
specific gene therapy are of interest. We constructed a
Cre/Lox reporter switch coupling telomerase promoter
specificity with Cytomegalovirus (CMV) promoter ac-
tivity, which is generally considered to be constitutively
high. In this approach, a telomerase-specific vector ex-
pressing Cre recombinase directs excisive recombina-
tion on a second vector, removing a transcriptional
blockade to CMV-dependent luciferase expression. We
tested switch activation in cell lines over a wide range
of telomerase promoter activities. However, Cre/Lox–
dependent luciferase expression was not enhanced
relative to expression using hTR or hTERT promoters
directly. Cell-specific differences between telomerase
and CMV promoter activities and incomplete sigmoid
switch activation were limiting factors. Notably, CMV
activity was not always significantly stronger than
telomerase promoter activity. Our conclusions provide
a general basis for a more rational design of novel
recombinase switches in gene therapy.
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Introduction
Telomerase is a ribonucleoprotein reverse transcriptase that
is minimally composed of RNA [human telomerase RNA
(hTR)] and catalytic [human telomerase reverse transcrip-
tase (hTERT)] subunits, which counteracts cell division–
associated attrition of the telomeres of linear chromosomes
by synthesizing new telomere DNA sequences from an
internal template sequence in hTR [1–3]. Most normal
cells do not express telomerase and are therefore subject
to telomere-dependent senescence. However, telomerase
activity is essential for immortalization of most cancer cells, and
its inhibition results in delayed-onset apoptosis [4–8]. Thus,
telomerase represents an exciting target for the development of
novel anticancer therapeutics [9–12].
Differential expression of telomerase between normal and
cancer cells is attributable to transcriptional regulation of hTR
and hTERT. Both transcripts are readily detectable in most
cancer cell lines and human malignancies, but are either
absent or at very low levels in normal cells and tissues. Cloned
hTR and hTERT promoter constructs also show selective
activity in cancer cells and have been exploited for transcrip-
tionally targeted gene therapy strategies, with the expectation
that therapeutic transgenes can be expressed at high levels,
specifically in cancer cells but not in normal cells [9,13–28].
Preclinical results of telomerase-specific gene therapy are
encouraging. Therapeutic transgene expression has been
demonstrated in multiple human cancer cell lines, whereas
normal cells are generally not targeted by the hTR and hTERT
promoters [9]. We previously reported that the telomerase
promoters drive an efficient and selective expression of the
bacterial nitroreductase (NTR) gene in several cancer cell
lines and xenografts, but not in normal cells [15,16]. NTR
catalyzes the rapid bioactivation of the relatively nontoxic pro-
drug CB1954, resulting in its conversion to a powerful alkyl-
ating agent. Activated CB1954 forms atypical DNA adducts
that are poorly repaired, leading to efficient p53-independent
apoptosis [29,30].
However, the telomerase promoters exhibit relatively weak
activity in some target cells [15,16,24]. This could restrict ther-
apeutic targeting potentials in applications such as enzyme/
prodrug therapy, where there is good correlation between
high transgene expression levels and significant therapeutic
effects. In this respect, we have found the hTERT promoter to
be particularly problematic. We have found that several cancer
cell lines are inefficiently targeted by the NTR/CB1954 com-
bination using the hTERT promoter. In our model, the stronger
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hTR promoter results in efficient therapeutic targeting of
more cell lines than hTERT. However, the hTR promoter is
also inefficient in some cases.
Therefore, strategies to improve the efficacy of telome-
rase gene therapy in cells with low promoter activity are of
interest [21,24]. One approach to improving the expression
levels of therapeutic transgenes in tissue-specific gene ther-
apy makes use of the Cre/Lox switch. Phage P1–derived
Cre recombinase catalyzes site-specific excision and circu-
larization of stuffer DNA sequences flanked at the 5V and 3V
ends by a specific 34-bp Cre-binding sequence (the LoxP
site). Thus, Cre/Lox technology provides a valuable tool for
studies of gene function [31,32].
Harnessed for gene therapy, a therapeutic transgene is
separated from a strong constitutive promoter by a LoxP-
flanked transcriptional termination signal. A weak tissue-
specific promoter of interest drives the expression of Cre
from a second vector, resulting in deletion of the stuffer
and derepression of transgene expression. Thus, selec-
tivity is neatly coupled with a constitutively high transcription
rate. Several groups have applied this strategy in cancer
gene therapy approaches [33–37]. Because the hTR and
hTERT promoters show weak activity in some cancer cells,
we reasoned that the Cre/Lox switch could be adapted to
extend the effective target cell range for telomerase-specific
gene therapy.
Here we report the development of a telomerase-specific
Cre/Lox switch regulating the expression of the luciferase
gene. In this system, luciferase expression is controlled by
the Cytomegalovirus (CMV) promoter and by a LoxP-flanked
stuffer fragment harboring the SV40 late polyadenylation
signal upstream of the luciferase gene. Expression of Cre,
mediated by hTR, hTERT, or SV40 promoters, excises the
stuffer facilitating the luciferase expression (Figure 1). This
model allowed us to test quantitatively whether a telomerase-
specific Cre/Lox switch could potentially enhance therapeutic
transgene expression levels relative to direct expression
through the hTR or hTERT promoters.
We selected a panel of four cancer cell lines with a
wide range of hTR and hTERT promoter activities in order
to examine switch activation over a range of low to high Cre
expression levels. Cre was expressed in a promoter- and
cell-specific manner, effectively derepressing luciferase ex-
pression over a wide range of concentrations. Unexpectedly,
however, the switch did not confer significantly enhanced
luciferase expression in any of the cells tested here.
These results were explained by cell-specific differences
between telomerase and CMV promoter activities, and by a
sigmoid relationship between Cre expression levels and
switch activation efficiency. Switch activation saturated at
very low Cre doses and increased Cre expression did not
confer increased luciferase expression. Because of these
attributes of Cre-mediated excision in cells, a very large
differential in selective and constitutive promoter activities
is required to confidently predict enhancement of gene
expression by the Cre/Lox switch. In our model, the CMV
promoter was not always significantly stronger than hTR
or hTERT. Importantly, because viral promoters have no
biomarkers of activity in human tissues, we conclude that
Cre/Lox switches using viral promoters cannot be applied in
a hypothesis-led fashion as experimental clinical therapeu-
tics. These factors limit the application of the Cre/Lox switch
in its current configuration for telomerase-specific gene
therapy and are also relevant for successful development
of Cre/Lox switches regulated by other promoters. Based on
these findings, we highlight possible modifications to signifi-
cantly improve the performance and predictability of other
novel Cre/Lox switches for gene therapy.
Materials and Methods
Cell Lines and Plasmids
In this study, we used the human cancer cell lines 5637
(bladder carcinoma), C33A (cervical carcinoma), A2780 (ovar-
ian adenocarcinoma), and A549 (lung adenocarcinoma).
The relative targeting efficiency of these cell lines by hTR-
or hTERT-directed enzyme–prodrug therapy has previously
been reported [15,16]. All vectors reported in this study
are based on the pGL3 reporter vector backbone (Promega,
Madison, WI). The hTR- and hTERT-luciferase reporter
vectors (pGL3-hTR and pGL3-hTERT) contain 867- and
572-bp fragments of the hTR and hTERT promoters, re-
spectively, which have previously been shown to direct the
selective expression of transgenes in tumor cells [15,16].
The control vectors pGL3-SV40 and pGL3-Basic were ob-
tained from Promega. To construct the hTR-, hTERT-, SV40-,
and promoterless-Cre expression vectors, the luciferase
gene was deleted from the pGL3 series of luciferase report-
ers by an NcoI/XbaI digest. The ends were made blunt with
Klenow fragment, and the vectors were religated. Cre was
inserted downstream of each promoter as a HindIII fragment
Figure 1. Regulation of luciferase expression by the Cre/Lox switch.
Transcription of the luciferase gene in vector LPS is repressed by the presence
of a LoxP-flanked stuffer fragment harboring the SV40 late polyadenylation
signal upstream of the luciferase gene. In the presence of Cre protein ex-
pression, in this case directed by the hTR and hTERT promoters, the stuffer
and polyadenylation signal are excised, leading to the derepression of CMV-
dependent luciferase expression.
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from pTurbo-Cre (a kind gift from Stephen Forrow). The
Cre-regulated reporter pGL3-CMV/LPS (vector LPS, ‘‘LoxP-
Stop’’) contains a 588-bp fragment of the CMV immediate-
early promoter separated from the luciferase gene by
LoxP-flanked stuffer DNA containing the SV40 late polyade-
nylation signal from pGL3-Basic. The positive control vector
pGL3-CMV (vector CMV) was generated by in vitro Cre-
mediated deletion of the stuffer DNA using recombinant Cre
(no. 69247; Merck Biosciences Ltd., Nottingham, UK).
Transfections and Luciferase Assay
All transfections were performed using Lipofectamine
transfection reagent, according to themanufacturer’s instruc-
tions (Invitrogen, Renfreshire, UK). A 1:1 DNA/Lipofectamine
ratio was used, and 250 ng/well reporter plasmid was trans-
fected in 96-well luminometer plates (Fisher Scientific UK,
Leicestershire, UK) together with varying amounts of hTR-,
hTERT-, SV40-, or promoterless-Cre expression vectors.
Thirty nanograms of pSV40-Renilla luciferase expression
plasmid (Promega) was also cotransfected in each well for
the normalization of hTR promoter activity. Forty-eight hours
posttransfection, cells were lysed and luciferase activities
were determined using Dual Luciferase Assay reagents
(Promega), according to the manufacturer’s instructions.
Each well was normalized to pSV40-Renilla using the for-
mula: LN = LW(RM / RW), which preserves the magnitude of
the firefly luciferase activity (LN = normalized firefly lucifer-
ase, LW= firefly luciferase activity of awell,RM=meanRenilla
activity of the plate, and RW = Renilla value of the well). It
should be noted that the regulatory elements in the pGL3-
SV40 and SV40-Renilla vectors are not directly comparable
because SV40-Renilla contains a chimeric intron used to
boost Renilla expression and has a different arrangement
of enhancer elements. All transfections were performed in
quadruplicate, and all experiments were repeated aminimum
of three times.
Western Blot Analysis
A2780, 5637, C33A, or A549 cells were transiently trans-
fected with 5 mg of hTR-, hTERT-, SV40-, or promoterless-
Cre expression plasmids using Lipofectamine reagent
(Invitrogen). Forty-eight hours posttransfection, protein
extracts were prepared in sodium dodecyl sulfate (SDS)
lysis buffer (10% SDS, 500 mM EDTA, and 1 M Tris–HCl).
Protein concentrations were estimated at OD595 using the
Bio-Rad protein assay (Bio-Rad Laboratories Ltd., Hemel
Hempstead, UK). Twenty micrograms of protein equivalents
was separated alongside 1 U of recombinant Cre (no. 69247;
Merck Biosciences Ltd.) by SDS-PAGE then blotted onto
PVDF filter (Millipore, Watford, UK) and blocked overnight at
4jC in PBS–Tween containing 5% nonfat dried milk. Filters
were probed for 2 hours with 1:3000 dilutions of primary anti-
Cre antibody (no. 69050-3; Merck Biosciences Ltd.) or
1:1000 dilutions of anti–a-tubulin antibody (Sigma, Ayrshire,
UK), then with a 1:3000 dilution of horseradish peroxidase
(HRP)–conjugated antirabbit secondary antibody. HRP was
detected using ECL HRP detection reagents (Amersham
Pharmacia, Buckinghamshire, UK).
Results
hTR, hTERT, and SV40 Promoters Direct Cre Expression
in Cancer Cell Lines
To develop a telomerase-specific Cre/Lox switch system,
we first constructed Cre recombinase expression vectors
either lacking a promoter (basic) or having Cre controlled by
hTR, hTERT, or SV40 promoters. All Cre expression vectors
and luciferase expression vectors described here are based
on the same vector backbone (pGL3; Promega) that con-
tains an insulating polyadenylation signal upstream of the
expression cassette, which is used to reduce background
(cryptic) transgene expression. Five micrograms of each
vector was transiently transfected in the human cancer cell
lines 5637 (bladder carcinoma), C33A (cervical carcinoma),
A2780 (ovarian adenocarcinoma), and A549 (lung adeno-
carcinoma). Western blot analysis was performed to detect
the expression of Cre protein. As a control, 1 U of recombi-
nant Cre protein was visualized alongside the extracts of
each cell line.
As shown in Figure 2A, all promoters directed the high-
level expression of Cre in C33A cells. A weak band was also
detected on the transfection of the promoterless vector in
these cells, indicating that this vector still harbors a cryptic
promoter activity in some cells. A2780 cells also expressed
comparatively high levels of Cre from the hTR and SV40
promoters, although the hTERT promoter appeared sub-
stantially weaker in this cell line. The 5637 cells expressed
even lower levels of Cre from each promoter, with hTERT-
directed expression being almost undetectable. The A549
cells showed the lowest expression levels of Cre using all
promoters. Thus, the hTR, hTERT, and SV40 promoters
direct cell- and promoter-specific Cre expressions. These
results correlate well with our previous analyses of thera-
peutic targeting efficiency using the NTR/CB1954 system in
these cell lines [15,16].
Repression of CMV Promoter Activity by LoxP-Flanked
Stuffer DNA Containing the SV40 Polyadenylation Signal
We next constructed a luciferase reporter vector in which
the CMV promoter is separated from the luciferase gene by
a LoxP-flanked stuffer fragment harboring the SV40 late
polyadenylation signal (vector LPS, LoxP-Stop; Figure 1).
The LoxP sites in this vector were cloned in ‘‘reverse’’ ori-
entation with respect to the CMV promoter, preventing the
introduction of false translational initiation codons (which
are present in the LoxP forward sequence after stuffer
excision) upstream of the luciferase. Incubating this plas-
mid in vitro with recombinant Cre deleted the stuffer, allow-
ing us to generate clones harboring a positive control
plasmid in which the stuffer is completely removed, mim-
icking the expected product of Cre-mediated recombination
in vivo (vector CMV; Figure 1). The activity of this vector
is indicative of the maximum possible CMV-dependent
expression in each cell line after the cotransfection of the
Cre expression vectors.
To determine the extent of luciferase repression by the
polyadenylation signal in vector LPS, we compared the
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luciferase activities of the CMV and LPS vectors (Figure 2B,
note the log scale). In C33A and A2780 cells, luciferase
activity was repressed by 70- and 80-fold, respectively,
whereas in A549 and 5637 cells, the polyadenylation signal
repressed luciferase activity by 329- and 388-fold, respec-
tively. Thus, incorporation of the polyadenylation signal
upstream of the luciferase gene significantly repressed
CMV promoter activity in all cells. For A2780, A549, and
5637 cells, these repressed values were not significantly
above the background luminescence detected in untrans-
fected wells. However, in C33A cells, the activity of vector
LPS was still substantially above background, suggesting
that the CMV promoter is sufficiently strong in these cells
for a fraction of transcripts to run through the polyade-
nylation signal. It should therefore be noted that the CMV
promoter/SV40 polyadenylation signal pairing may be leaky
in some cells and that this could be a potential source of off-
target transgene expression. To optimize the system, it may
be necessary to include alternative or additional transcrip-
tional silencing elements.
hTR, hTERT, SV40, and Basic Promoter Activities
Relative to CMV
To enhance telomerase-specific transgene expression
by this system, the CMV promoter must be more active than
hTR or hTERT within target cells. We therefore directly quan-
tified the activity of all promoters in each cell line, using hTR-,
Figure 2. Relative activities of promoter constructs. (A) Expression levels of Cre protein. Cell lines indicated were transiently transfected with 5 g of expression
constructs encoding Cre recombinase under the control of the promoters indicated. Forty-eight hours posttransfection, 20 g of protein extracts was probed for the
expression of Cre and a-tubulin as loading controls. Western blot analyses were repeated three times. (B) Repression of CMV promoter activity by stuffer DNA.
Two-hundred fifty nanograms of vector CMV or vector LPS, harboring a polyadenylation signal downstream of the CMV promoter, was transiently transfected in
quadruplicate. Forty-eight hours posttransfection, luciferase activities were determined. Results are the pooled means and standard errors of three independent
experiments for each cell line. (C) Relative promoter activities. Cell lines were transiently transfected in quadruplicate with 250 ng of hTR-, hTERT-, SV40-, basic
(promoterless) – , or CMV-luciferase expression plasmids. Forty-eight hours posttransfection, luciferase activities were determined. Results are the pooled means
and standard errors of three independent experiments for each cell line.
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hTERT-, SV40-, basic (promoterless)-, and CMV-luciferase
reporters. Two hundred fifty nanograms of each reporter was
transiently transfected and, 48 hours posttransfection, lucif-
erase activities were determined (Figure 2C). The relative
luciferase activities for hTR, hTERT, and SV40 promoters
between cell lines correlated well with our Western blot
analysis results (compare Figure 2, A and C). It should be
noted that above-background luminescence was detected
on the transfection of the promoterless luciferase expression
vector in both C33A and A2780 cells, although Cre expres-
sion was not detected by Western blot analysis on the
transfection of the equivalent promoterless Cre expression
vector in A2780 cells. Importantly, CMV promoter activity
varied significantly between cell lines.
The CMV promoter was frequently stronger than hTR or
hTERT, although the differential was small in some cases. In
C33A cells, for example, the CMV promoter was only 2.6-
and 4-fold stronger than the hTR and hTERT promoters,
respectively. Interestingly, in A2780 cells, CMV promoter
activity was lower than hTR activity. Thus, in A2780 cells,
use of the CMV promoter to drive therapeutic transgene
expression in the context of this system will be less effi-
cient than using hTR alone. The CMV promoter was also
only 1.3-fold more active than the hTERT promoter in these
cells. Specific implications of this finding are considered in
the Discussion section. In contrast, in the cells with weaker
hTR and hTERT activities, CMV activity was 8.7- and 15.7-
fold stronger than hTR and hTERT in A549 cells, respec-
tively, and was 7.2- and 44-fold stronger than hTR and
hTERT in 5637 cells, respectively. It was therefore expected
that the telomerase-specific Cre/Lox recombination should
derepress the stronger CMV promoter activity and thus
significantly enhance luciferase expression in these latter
cells, relative to use of the hTR or hTERT promoters alone.
Telomerase-Specific Cre Expression Activates the
Recombinase Switch
To test the performance of the switch, we cotransfected
the LPS reporter with a titration of each Cre expression
vector and measured the fold induction of luciferase activity
(2:1, 8:1, and 32:1 vector LPS/Cre expression vector ratios).
The CMV reporter with and without Cre expression was
also included to estimate the activation efficiency of the
switch. As shown in Figure 3, A–D, cotransfection of the
hTR-, hTERT-, or SV40-Cre vectors induced the activity of
the LPS reporter in a promoter-, cell-, and dose-dependent
manner, indicating that the switch was functional. As ex-
pected, Cre transfection had no significant effect on control
CMV promoter activity.
Cre expression led to a strong induction of luciferase
activity in C33A cells. At the highest ratio tested in this
experiment, the fold inductions ranged from 20- to 29-fold.
However, these values were significantly lower than the
maximum 70-fold difference between LPS and CMV activi-
ties. Interestingly, fold activation profiles were relatively
similar between promoters and across the concentration
range despite differences in the activities of the hTR, hTERT,
and SV40 promoters. We also noted that the high concen-
tration of basic-Cre led to a sevenfold induction of activity. In
A2780 cells, a strong induction was observed for all pro-
moters (range, 52- to 62-fold). Again, these values were
lower than the maximal 80-fold difference between CMV and
LPS promoter activities. Despite more pronounced differ-
ences in hTR and hTERT promoter activities than in C33A
cells, however, both the hTR- and hTERT-Cre expression
vectors resulted in similar switch activations across the
concentration range. In these cells, SV40-Cre induced lucif-
erase expression more than hTR- or hTERT-Cre at the lower
ratios. We noted that cotransfection of the basic vector,
which lacks a promoter, also resulted in significant induction
of LPS at both the 2:1 and 8:1 ratios in these cells. Together,
these data suggest that the Cre/Lox switch is extremely sen-
sitive to activation by very low Cre doses in these cells, but
may be less sensitive to differential Cre expression levels
at higher doses in these cells.
In 5637 cells, neither hTR-Cre nor hTERT-Cre resulted in
significant induction of CMV promoter activity. SV40-Cre
cotransfection induced activity by 20-fold, but the maximum
achievable induction was 388-fold in this cell line, suggesting
that, overall, activation efficiency was extremely poor in
these cells. Finally, in A549 cells, which had the weakest
hTR and hTERT activities, the profile of switch activation by
the SV40 promoter was higher than that observed for hTR or
hTERT, although hTR and hTERT were themselves rela-
tively similar across the concentration range. The hTR-Cre
vector led to 24-, 11-, and 9-fold induction of LPS, whereas
hTERT-Cre led to 17-, 11-, and 6-fold activation. In contrast,
SV40 led to 72-, 38-, and 42-fold activation at the ratios
tested. However, because the SV40 promoter is 22-fold
stronger than the hTERT promoter in these cells, it would
have been reasonable to expect a greater difference be-
tween activation levels induced by hTERT-Cre or SV40-Cre.
Sigmoid Dose–Response Characteristics of Cre/Lox
Switch Activation
To determine whether induction of the Cre/Lox switch
leads to enhancement of luciferase activity relative to direct
expression through the hTR or hTERT promoters, we exam-
ined the relationship between the specific promoter activity
of hTR-, hTERT-, SV40-, or basic-luciferase vectors (x-axis)
and the level of switch activation achieved by hTR-, hTERT-,
SV40-, or basic-Cre cotransfection in the switch system
( y-axis) at the 2:1 ratio. As shown in Figure 4, A–D, both
specific promoter activities and switch activation efficiency
are represented as a percentage of the activity of the CMV
promoter alone, which was included as a control in all ex-
periments. Therefore, enhancement can be inferred, where
y > x. The relationship between specific promoter strength
and switch activation efficiency appeared roughly sigmoid for
all cell lines.
In C33A cells, hTERT promoter activity alone was 24.6%
of CMV promoter activity (± 2.9%). Cotransfection of a 2:1
LPS/hTERT-Cre ratio resulted in LPS induction to 28.9% of
CMV activity (± 5.8%). In these cells, hTR promoter activity
alone was 37.1% of CMV (± 5.5%), whereas when the hTR
promoter was used to drive Cre expression, the activated
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switch activity was 39.1% of CMV (± 8.4%). As previously
noted, the hTR promoter was actually stronger than CMV
in A2780 cells and, therefore, there could have been no
enhancement by activating the switch with this promoter.
However, hTERT promoter activity in A2780 was 76.2% of
CMV (± 10.8%). When hTERT was used to drive Cre
expression, vector LPS was activated to only 67.4% of
CMV activity (± 9.6%). Thus, although high-level switch ac-
tivation efficiency was achieved in these cell lines, low dif-
ferentials between hTR/hTERT and CMV promoter activities
Figure 3. Activation of the Cre/Lox switch. Two-hundred fifty nanograms of vector LPS or vector CMV was transiently transfected in quadruplicate in each cell line
alone or in combination with the indicated hTR-, hTERT-, SV40-, or basic (promoterless) –Cre expression vectors at 2:1, 8:1, or 32:1 ratios (LPS or CMV: Cre
expression vector), as indicated. For vector CMV, only the 2:1 ratio is shown (rightmost four bars). Results are pooled means and standard errors of three
independent experiments for each cell line. (A) C33A cells; (B) A2780 cells; (C) 5637 cells; (D) A549 cells.
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meant that no significant benefit was conferred by the Cre/
Lox system relative to the expression of luciferase directly
from either hTR or hTERT promoters.
In A549 cells, hTERT and hTR promoter activities were
only 6.4% (± 1%) and 11.2% (± 1.3%) relative to CMV pro-
moter activity, respectively, and it was therefore expected
that the Cre/Lox system might enhance luciferase expres-
sion. Interestingly, activation of the switch resulted in relative
activities of only 6.3% (± 2.1%) for hTERT-Cre expression
and 9% (± 3.2%) for hTR-Cre expression. The lack of en-
hancement in these cells appeared to be due to a low peak in
maximum efficiency of switch activation because the much
stronger SV40 promoter (150% of CMV promoter strength)
led to only 21.7% activation. Similarly, in 5637 cells, the hTR
and hTERT promoter activities alone were 13.8% (± 3.4%)
and 2.2% (± 0.3%) of CMV promoter activity, whereas on
cotransfection of hTR-Cre and hTERT-Cre, the switch was
activated only to 1.2% (± 0.4%) and 0.4% of the level of CMV
promoter activity alone. Therefore, the Cre/Lox switch actu-
ally restricted the expression that could be achieved relative
to using either promoter alone in this cell line, mainly be-
cause of poor overall activation.
These data indicate that switch activation exhibits a broad
plateau phase in all cell lines tested, at which increasing
promoter activity—and hence Cre expression level—does
not lead to equivalent linear increases in switch induction
(‘‘saturation efficiency’’). Saturation efficiency differed signifi-
cantly between the cell lines but was always significantly
lower than 100%. Because we have shown that the activities
of the hTR, hTERT, and SV40 promoters correlate well with
Cre expression level in each cell line, these data also sug-
gested that a relatively low ‘‘saturation dose’’ of Cre expres-
sion was required in each cell line to reach saturation
efficiency. To test this relationship, we performed a titration
of the SV40-Cre expression vector over a > 3-log concen-
tration range using a fixed concentration of 250 ng of vector
LPS (500–0.24 ng of SV40-Cre, 1:2 to 1000:1 ratios).
As shown in Figure 5, A–D, the titration experiment
confirmed that activation of the Cre/Lox switch follows a
sigmoid-like dose response in all cells tested here. Impor-
tantly, saturation efficiencies were very different between cell
lines, with both A2780 and C33A cells reaching 50% to 60%
maximal activation, whereas A549 cells reached only ap-
proximately 30% efficiency and 5637 cells reached only 10%
activation. It is unclear how cell specific factors might influ-
ence the maximum activation efficiency in this system. One
possibility is that cell-specific expression of CMV promoter-
binding factors might block the access of Cre to its promoter-
proximal site. Alternatively, cell-specific differentials in nuclear
import or uncharacterized posttranslational modifications of
Cre protein could play a role. Whatever the mechanistic
basis for this finding, the data reported here have significant
implications for the rational development of novel Cre/Lox
switch systems for gene therapy.
Discussion
Preclinical telomerase-directed gene therapy strategies
show an extremely broad target cell range, coupled with a
high degree of selectivity for tumor cells over normal cells [9].
However, for approaches such as enzyme/prodrug therapy,
Figure 4. The Cre/Lox switch does not enhance telomerase-specific
luciferase expression. Individual specific promoter activities measured for
the transfection of 250 ng of hTR-, hTERT-, SV40-, and basic-luciferase
expression vectors are represented on the x-axis as a percentage of CMV
promoter activity in each cell line. Induced luciferase activity of the Cre/Lox
switch after the cotransfection of hTR-, hTERT-, SV40-, and basic-Cre
expression plasmids with 250 ng of vector LPS at a 2:1 ratio (LPS/Cre) is
shown on the y-axis, also as a percentage of control CMV promoter activity
(maximal activation efficiency) in each cell line. The criterion used to dem-
onstrate enhancement is therefore y > x. Each data point represents means
and standard errors from three pooled independent experiments performed
in quadruplicate. Squares: basic-luciferase (x-axis), basic-Cre ( y-axis);
triangles: hTERT-luciferase (x-axis), hTERT-Cre ( y-axis); diamonds: hTR-
luciferase (x-axis), hTR-Cre ( y-axis); crosses: SV40-luciferase (x-axis), SV40-
Cre ( y-axis). (A) C33A cells; (B) A2780 cells; (C) 5637 cells; (D) A549 cells.
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which may require high transgene expression levels, hTR,
and particularly hTERT, promoter activities may occasionally
be too low in some cancer cells to result in effective targeting
[15,16]. Therefore, systems to enhance telomerase-specific
transgene expression while maintaining selectivity may be
advantageous in some cases. In this report, we tested a
telomerase-specific Cre/Lox–dependent switch to deter-
mine whether coupling the specificity of the hTR and hTERT
promoters with the activity of the CMV promoter could in-
crease the likelihood of effectively targeting cancer cells with
lower telomerase promoter activities in gene therapy appli-
cations. The switch was tested using a cell panel that exhibits
a wide range of telomerase promoter activities, thus allowing
us to examine different levels of Cre expression.
The hTR, hTERT, and SV40 promoters directed cell-
specific levels of Cre expression that were well correlated
with individual promoter strengths measured by luciferase
assay. We also showed that incorporation of the SV40
polyadenylation signal in a LoxP-flanked stuffer fragment
downstream of the CMV promoter effectively repressed
CMV-dependent luciferase expression. However, in C33A
cells, a significant level of luciferase activity was still detected
even without Cre expression, indicating that the SV40 poly-
adenylation signal is not sufficient to completely block the
activity of the CMV promoter in all cells. This configuration of
the Cre/Lox switch may therefore display leakiness in some
cells, which might give rise to off-target effects if the system
was widely applied. The relative silencing of transgene ex-
pression could be improved by incorporation of additional or
alternative silencing elements in the stuffer.
Cotransfection of Cre expression plasmids derepressed
luciferase activity, indicating that the basic system was func-
tional. However, the degree of switch activation was not well
correlated with specific promoter activities and, thus, relative
expression levels of Cre protein. Indeed, even cotransfection
of the promoterless-Cre vector significantly induced the
switch in A2780 and C33A cells. Titration of SV40-Cre re-
vealed a sigmoid dose response characterized by a plateau
of activation efficiency (saturation efficiency) at very low Cre
doses (saturation dose).
These results are consistent with the kinetics of Cre-
mediated excision in vitro [38,39]. The behavior of Cre
in vitro appears to be related to the stoichiometry and dis-
sociation kinetics of the recombination complex and possibly
to a time-dependent inactivation or sequestration mecha-
nism. We show here that these characteristics are retained
in the cellular milieu. Importantly, for gene therapy, our study
indicates that dose response and saturation efficiency dif-
fer markedly between cell lines, with A2780 and C33A cells
both reaching approximately 60% of full efficiency but with
A549 and 5637 cells reaching only approximately 30% and
10%, respectively.
These data may explain the previous observation that
effective enhancement of tissue-specific gene therapy by
the Cre/Lox switch requires an extremely large differential
between the activities of selective and constitutive pro-
moters [33]. Our results indicate that optimal effects will be
expected mainly for selective promoters with activity differ-
ing significantly from the saturation efficiency of the consti-
tutive promoter in individual cell lines. Furthermore, there is
no net benefit in terms of increased switch activation effi-
ciency by increasing Cre expression levels above the satu-
ration dose. Thus, the differential in promoter activities will
Figure 5. Sigmoid dose response of switch activation. Cells were transiently
transfected with 250 ng of vector LPS together with a titration of SV40-Cre
expression vector or with vector CMV alone. Forty-eight hours posttransfec-
tion, luciferase activities were determined. The concentrations of SV40-Cre
ranged from 500 to 0.24 ng (LPS/SV40-Cre ratio ranged from 1:2 to 1000:1).
Luciferase activities are represented as a percentage of the activity of vector
CMV (maximal activation efficiency). Results are the pooled means and
standard errors derived from three independent experiments in each cell line.
(A) C33A cells; (B) A2780 cells; (C) 5637 cells; (D) A549 cells.
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also be optimal when the selective promoter is weak enough
to direct Cre expression levels that lie close to the saturation
dose. Because these parameters are likely to vary widely, it
may prove difficult to make any general predictions regarding
the fold difference required for enhancement.
As we show here, either a low differential between se-
lective and constitutive promoter activities or a low saturation
efficiency can limit the general applicability of this system.
Therefore, our results do not support the development of the
system in its current configuration for telomerase-specific
enzyme–prodrug therapy because the telomerase promoters
already show acceptable activity in a range of target cells.
Our results do not indicate, however, that the Cre/Lox
system has no utility for telomerase gene therapy. Indeed,
because hTERT promoter activity appeared to be close to
the saturation dose in all cell lines, it is very likely to be low
enough in some cells to result in enhancement given that the
other variables are favorable. The use of a stronger consti-
tutive promoter could significantly improve the chances of
enhancement using an hTERT-specific switch for cancer
therapy. Interestingly, the system might also be used to
selectively target gene expression to normal stem cells of
noncancer patients, which should be the main telomerase-
positive populations. The current switch may also have utility
if high expression levels can be sacrificed in return for se-
lectivity, as may be the case for expression of siRNA.
Overall, only a subset of cancers will be good targets for
this switch in its current configuration. Additionally, because
of the dose–response profile of the Cre-mediated excision
that we describe, off-target stuffer excision in nontarget cells
with low telomerase could also result in transgene expres-
sion. However, an improvement could be made to limit
cryptic activation in nontarget cells. Cre-mediated recombi-
nation of the mutant LoxAT sequence is inhibited at low Cre
concentrations in vitro, and although the final saturation
efficiency for LoxAT is equivalent with that of LoxP, more
Cre is needed to maximally recombine LoxAT [39]. LoxAT
thus has the potential to introduce a low-threshold Cre dose
requirement for initial switch activation, which could reduce
the potential for off-target effects.
Finally, we suggest a critical improvement for novel Cre/
Lox switch systems to progress to successful clinical testing:
because a large differential between selective and constitu-
tive promoter activities is essential to predict enhancement
by this system, it is also essential to use a constitutive
promoter with activity that is estimable by standard tech-
niques in patient biopsy samples. In this respect, viral
promoters are a major disadvantage in this system because
they have no acceptable biomarkers of activity. Our data
show that, in A2780 cells, the hTR and hTERT promoters
were stronger than CMV. Thus, viral promoters can restrict
the efficacy of this system in an unpredictable way, rendering
the approach extremely difficult to apply to hypothesis-led
trials. A more predictable approach requires the use of a
strong human housekeeping gene promoter. Thus, specific
and constitutive target RNA levels could be judged in clini-
cal samples, facilitating streamlined patient selection from
clinical specimens.
In conclusion, telomerase-directed gene therapy con-
tinues to show promise in preclinical models. However, there
is a hypothetical need to test strategies for overcoming
low promoter activity in some target cells. Although we have
not found significant benefits to the Cre/Lox system in the
cells tested here, different configurations of this system
might have greater utility. It is significant that telomerase-
dependent expression of at least 12 different therapeutic
transgenes has been reported, in addition to the develop-
ment of telomerase-specific replicating adenoviral vectors
[9]. Thus, tumor cells that are not susceptible to killing by any
one approach may be targeted very efficiently by another.
Furthermore, telomerase-specific gene therapies comprise
the basic toolkit of both hTR and hTERT promoters, both of
which show selective but widely different activities. There-
fore, there is a suitably broad base of approaches with which
to begin the clinical assessments that will ultimately define
the efficacy of telomerase-specific targeting.
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